Proactive Investors - Run By Investors For Investors

Sirtex Medical to present liver cancer study results in the Netherlands

Sirtex Medical (ASX:SRX) will present the clinical study results of its treatment for liver cancer at the International Liver Congress in the Netherlands during April 2017.
Sirtex Medical to present liver cancer study results in the Netherlands
Sirtex Medical to present liver cancer study results in the Netherlands

Sirtex’s SARAH study is a Phase III multi-centre prospective randomised open-label study for patients in France with advanced hepatocellular carcinoma (HCC).

HCC is the most common form of primary liver cancer, a cancer that starts in the liver.

The SARAH study will be presented at the International Liver Congress on Saturday, 22nd April 2017.

The SARAH study directly compares Sirtex’s SIR-Spheres® Y-90 resin microspheres versus the current standard-of-care systemic therapy, sorafenib.

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via selective internal radiation therapy (SIRT), directly to liver tumours.

The devices are approved for supply in key markets, such as the U.S., European Union and Australia.

The primary endpoint of the SARAH study is overall survival with secondary endpoints including safety and tolerability, tumour response rates and quality of life scores.

SARAH is the largest randomised study ever to compare selective internal radiation therapy using SIR-Spheres microspheres against the standard-of-care systemic therapy in the treatment of HCC.

View full SRX profile View Profile

Sirtex Medical Ltd Timeline

Newswire
January 31 2017

Related Articles

bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
1538160791_petri-dishes.jpg
September 29 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use